 Ruthenium has numerous properties that qualify it as an antineoplastic drug contender.While platinum-based compounds have served as very successful anti-cancer drugs, they have several limitations including their side effects, as well as ineffectiveness against certain types of cancer.Bergamo and Sava speculated in 2011 that some of these issues might be resolved with the use of a ruthenium substitute.